EGFR and lung adenocarcinoma: To date, somatic mutations in TP53 are the most prevalent co-mutation in EGFR-mutant lung adenocarcinoma (LUAD) with a frequency of 54.6–64.6% and several studies have identified TP53 co-alteration as a negative prognosis marker, with consistently predicting worse clinical outcomes receiving EGFR-TKI therapy (27).